



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / مني مغربي أحمد

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد





Serum IL-22 as a novel non-invasive biomarker in diagnosis and assessment of activity in ulcerative colitis patients

Thesis

*Submitted for Partial Fulfillment of Master Degree
in INTERNAL MEDICINE*

By

Mohamed Sayed Mohamed Ali Kortam

M.B.B.Ch

Supervised By

Prof .Dr. Sherif Mounir Mohamed Farag

*Professor of Internal medicine, Gastroenterology and Hepatology
Ain Shams University*

Prof .Dr. Ahmed Samir Abd El-Sadek Abo Halima

*Assistant professor of internal medicine, gastroenterology and hepatology
Ain Shams University*

Dr. Heba Ahmed Faheem

*Lecturer of internal medicine, gastroenterology and hepatology
Ain Shams University*

Faculty of medicine - Ain Shams University

2022

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **Allah**, the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound gratitude to **Prof .Dr. Sherif Mounir Mohamed Farag**, Professor of Internal medicine, Gastroenterology and Hepatology Ain Shams University, for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

*I am also delighted to express my deepest gratitude and thanks to **Prof .Dr. Ahmed Samir Abd El-Sadek Abo Halima**, Assistant professor of internal medicine, gastroenterology and hepatology Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

*I am deeply thankful to **Dr. Heba Ahmed Faheem**, Lecturer of internal medicine, gastroenterology and hepatology Ain Shams University, for her great help, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Mohamed Sayed Kortam

Contents

<i>Items</i>	<i>Page</i>
List of Tables	II
List of Figures	III
List of Abbreviation	IX
Introduction	1
Aim of the Work	5
Review of Literature	6
■ Ulcerative Colitis	6
■ Interleukin-22	38
Patients and Methods	51
Results	62
Discussion	106
Summary	122
CONCLUSIONS	133
RECOMMENDATIONS	126
References	127
Arabic Summary	1

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
1	Comparison between Control group (no. =15) and Patient group (no. =40) regarding Age, Sex, Smoking status	62
2	Distribution of the Patient group according to Severity	64
3	Distribution of the Patient group according to Abdominal pain, Diarrhea, Bleeding per rectum, Weight loss, Urgency and Extra intestinal manifestations	65
4	Distribution of the Patient group according to Number of motions	66
5	Comparison between Control group (no. =15) and Patient group (no. =40) regarding to Temperature	68
6	Comparison between Control group (no. =15) and Patient group (no. =40) regarding Laboratory investigations	69
7	Comparison between Control group (no. =15) and Patient group (no. =40) regarding IL-22 (Pg/ml)	72
8	Distribution of the Patient group according to Colonoscopy	73
9	Distribution of the Patient group according to Extent and Mayo Score	75
10	Distribution of the Patient group according to Histological examination	77
11	Comparison between Control group (no. =15), Activity group (no. =20) and Remission group (no. =20) regarding Age, Sex and Smoking status	78
12	Comparison between Activity group (no. =20) and Remission group (no. =20) regarding Number of motions, Abdominal pain, Diarrhea, Bleeding per rectum, Weight loss, Urgency and Extra intestinal manifestations	79

<i>Table No.</i>	<i>Title</i>	<i>Page</i>
13	Comparison between Control group (no. =15), Activity group (no. =20) and Remission group (no. =20) regarding Laboratory investigations	81
14	Comparison between Control group (no. =15), Activity group (no. =20) and Remission group (no. =20) regarding IL-22 (Pg/ml)	85
15	Comparison between Activity group (no. =20) and Remission group (no. =20) regarding Colonoscopy	87
16	Comparison between Activity group (no. =20) and Remission group (no. =20) regarding Extend and Mayo Score	88
17	Comparison between Activity group (no. =20) and Remission group (no. =20) regarding Histological examination	90
18	Correlation between IL-22 (Pg/ml) With Age, Number of motions, Examination, Laboratory investigations and Mayo Score.	92
19	Relation between IL-22 (Pg/ml) With Colonoscopy, Histological examination and Extend.	97
20	Correlation between IL-22 (Pg/ml) With Age, Number of motions, Examination, Laboratory investigations and Mayo Score.	98
21	Correlation between IL-22 (Pg/ml) With Age, Number of motions, Examination, Laboratory investigations and Mayo Score.	101
22	Relation between IL-22 (Pg/ml) With Colonoscopy, Histological examination and Extend.	102
23	ROC curve (Patient and Control) group regarding IL-22 (Pg/ml)	103
24	ROC curve (Activity and Remission) group regarding IL-22 (Pg/ml)	104

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page</i>
1	Increase in worldwide incidence of ulcerative colitis over time.	8
2	Ulcerative colitis phenotypes by Montreal Classification.	14
3	Suggested treatment approach algorithm for mild to moderate ulcerative colitis.	24
4	Suggested treatment approach algorithm for moderate to severe ulcerative colitis.	29
5	Role of IL-22 in the intestine during homeostasis.	40
6	Role of IL-22 in IBD/GVHD and cancer.	46
7	shows the difference between (Control group and Patient group) regarding Sex.	63
8	shows the difference between (Control group and Patient group) regarding Age.	63
9	Distribution of the studied cases according to Severity.	64
10	Distribution of the studied cases according to Complain.	66
11	shows the difference between (Control group and Patient group) regarding Number of motions	68
12	shows the difference between (Control group and Patient group) regarding Wbcs	70
13	shows the difference between (Control group and Patient group) regarding ESR	71
14	shows the difference between (Control group and Patient group) regarding CRP	71
15	shows the difference between (Control group and Patient group) regarding IL-22(pg/ml)	72
16	Distribution of the studied cases according to Colonoscopy.	74
17	Distribution of the studied cases according to Extent	76
18	shows the difference between (Control group, Activity group and Remission group) regarding number of motions	80
19	shows the difference between (Activity group and Remission group) regarding Abdominal pain, Diarrhea, Bleeding per	80

<i>Fig. No.</i>	<i>Title</i>	<i>Page</i>
	rectum, Weight loss, Urgency and Extra intestinal manifestations.	
20	shows the difference between (Control group, Activity group and Remission group) regarding Wbcs.	83
21	shows the difference between (Control group, Activity group and Remission group) regarding platelets	83
22	shows the difference between (Control group, Activity group and Remission group) regarding ESR.	84
23	shows the difference between (Control group, Activity group and Remission group) regarding CRP	84
24	shows the difference between (Control group, Activity group and Remission group) regarding IL-22 (Pg/ml).	86
25	shows the difference between (Activity group and Remission group) regarding Colonoscopy	87
26	shows the difference between (Activity group and Remission group) regarding Mayo Score	89
27	shows the difference between (Activity group and Remission group) regarding Histological examination	91
28	Positive Correlation between IL-22 (Pg/ml) and Number of motions	94
29	Negative Correlation between IL-22 (Pg/ml) and Wbcs	94
30	Positive Correlation between IL-22 (Pg/ml) and ESR.	95
31	Negative Correlation between IL-22 (Pg/ml) and CRP	95
32	Positive Correlation between IL-22 (Pg/ml) and Mayo Score	96
33	Negative Correlation between IL-22 (Pg/ml) and CRP	99
34	Positive Correlation between IL-22 (Pg/ml) and Mayo Score	100

List of Abbreviations

<i>GD</i>	<i>Graves' Disease</i>
5-ASA	5-aminosalicylic acid
Ahr	Aryl hydrocarbon receptor
AMPs	Antimicrobial proteins
BaP	benzo (α) pyrene
BCLxl	B cell lymphoma
CD	Crohn's disease
CRP	C-reactive protein
DC	dendritic cell
DNBS	dinitrobenzene sulfonic acid
DSS	dextran sulfate sodium
ER	endoplasmic reticulum
FC	Fecal calprotectin
FMT	fecal micro biota transplantation
FUT2	fucosyltransferase 2
GDNF	glial cell–derived neurotrophic factor
GVHD	graft-versus-host disease
GWAS	genome wide association studies
HS	highly significant
IBD	Inflammatory bowel disease
IBM SPSS	Statistical Package for Social Science

IECs	Intestinal epithelial cells
IFN	interferon
IgA	immunoglobulin A
IL	interleukin
IL-22	Interleukin-22
IL-5	interleukin-5
ILC3	innate lymphoid type 3
ILCs	Innate lymphoid cells
IMID	immune-mediated inflammatory disease
IPAA	ileal pouch-anal anastomosis
ISCs	intestinal stem cells
MAdCAM	mucosal addressin cell associated molecule
MHC	major histocompatibility complex
MLN	mesenteric lymph node
mTOR	mechanistic target of rapamycin
Mϕ	macrophage
NK T cell	natural killer T cell
NS	non significant
OR	odds ratio
PPAR-γ	peroxisome proliferator-activated receptor gamma
S	significant
SES-CD	Simple Endoscopic Score for CD

SNPs	single nucleotide polymorphisms
TCDD	tetrachlorodibenzo-p-doxin
TGF	transforming growth factor
Th	T-helper cell
Th1	T helper type 1
TNF-α	tumour necrosis factor- α
TREG	regulatory T cell
Tyk2	tyrosine kinase 2
UC	ulcerative colitis
UC-CRC	UC-related carcinogenesis

INTRODUCTION

Crohn's disease (CD) and ulcerative colitis (UC) are chronic idiopathic inflammatory bowel diseases, characterized by an inappropriate and uncontrolled immune response, stimulated by the gut micro biome in a genetically susceptible host.

Typically, patients with IBD follow a disease course consisting of alternating exacerbations and periods of remission (*Bourgonje et al., 2019*).

In IBD, the extent of inflammatory disease activity is preferably established by endoscopy, that is translated to validated scoring systems, such as the Mayo endoscopic sub score for UC and the Simple Endoscopic Score for CD (SES-CD) (*Bourgonje et al., 2019*).

Endoscopic examination is the most reliable approach for diagnosing the presence and extent of IBD disease activity but it has several disadvantages, such as a high patient burden and risks of serious complications, like bowel perforation or bleeding, it is also costly and time-consuming. So, Alternatives for endoscopy are needed (*Benitez JM., 2013*).

Biomarkers for endoscopic disease activity have been explored to predict the level of mucosal inflammation in IBD.

Fecal calprotectin (FC) and serum C-reactive protein (CRP) levels are now widely used and considered predictive markers for the degree of inflammation, but also show inconsistent correlation with mucosal inflammation when compared to endoscopy; This illustrates the need for better diagnostic measures for IBD exacerbations that can also be applied to patients with subclinical disease activity (*Bourgonje et al., 2019*).

The ideal inflammatory marker would be sensitive and specific, easy to perform, non invasive, has a low cost, and has a good prognostic value. It should also be reproducible between individuals and laboratories (*Yarur et al., 2017*).

The current opinion about IBD pathogenesis is that the disease results from interactions between environmental factors, mainly microbes of the intestinal lumen and their products, and dysregulation of immune responses in genetically susceptible individuals.

Certain harsh environments that may affect barrier integrity (to increase barrier permeability to luminal macromolecular substances, such as protein antigens and microbial products) and over-absorption of luminal microbial products (which has been ascribed to a number of mucosal

pathologies) can lead to an over-activation of immune system, thus resulting in mucosal inflammation.

IL-22 is a member of the IL-10 subfamily, which was identified as T-cell–derived cytokine.

Expression of IL22 is induced in several human inflammatory conditions including IBD.

IL-22 was recently discovered to be mainly produced by both adaptive and innate immune cells.

Several cytokines and many of the transcriptional factors and T regulatory cells are known to regulate IL-22 expression through activation of signal transducer and activator of transcription 3 signaling cascades.

Findings have confirmed the potential role of the IL-22 gene in the pathogenesis of UC and suggest that IL-22 might be involved as a defense mechanism by enhanced mucus production, IL-22 prevents tissue damage and aids in its repair.

IL-22 plays a critical role in the regeneration of damaged epithelial monolayers and stimulates antimicrobial peptide generation. Importantly, the ability of IL-22 to promote intestinal wound healing and proliferation of intestinal epithelial cells in mice and humans has been reproducibly demonstrated by independent groups using different